-
Join BioNTech at WCLC 2026: Learn More About Gotistobart and the PRESERVE-003 Trial in sqNSCLC
Learn more about gotistobart and the PRESERVE-003 trial, including updated overall survival data being presented at WCLC 2026. Visit BioNTech at Booth #823 to learn about this investigational antibody.
-
Join Bayer at WCLC 2026: Connecting Science, Clinical Practice, and Patient-Centered Care in HER2-Mutant NSCLC
Explore the evolving management of HER2-mutant NSCLC through a Meet the Expert series at the Bayer booth #123 on September 13th and 14th and a dedicated Bayer-sponsored symposium on September 12th at WCLC 2026! Hear from leading experts at interactive booth sessions and a dynamic symposium. MA-M_SEV.-KR-0016 | July 2026
-
Empowering shared decision-making through The 3rd Opinion
The growing range of treatment options for EGFR-mutated non-small cell lung cancer (NSCLC) has made first-line decisions more complex and more critical. The 3rd Opinion, the patient’s own opinion, is a new term created by Johnson & Johnson that advocates for a shift in mindset: one where patients are supported to speak up, share what…
-
Medical Crossfire®: ADCs and Bispecifics in Lung Cancer, Hype, Hope, or a New Standard of Care?
September 12, 2026 10:30 AM – 11:30 AM KST (Korean Time) | Seoul, South Korea Overview: ADCs and bispecific antibodies are rapidly changing the treatment landscape in thoracic oncology. In NSCLC, several ADCs and bispecific antibodies are already reshaping established treatment paradigms. In SCLC, novel bispecific T-cell engagers and ADCs are driving meaningful advances in…
Sign up for news updates
